Icatibant acetate is primarily used in the treatment of acute attacks of hereditary angioedema (HAE) in adults. HAE is a rare genetic condition characterized by sudden episodes of swelling in various parts of the body, including the skin, abdomen, and airways. Icatibant acetate works by blocking the action of bradykinin, a peptide that contributes to the swelling and pain associated with HAE attacks. It is administered as a subcutaneous injection, providing rapid relief from symptoms. The drug is particularly valuable in managing life-threatening airway swelling, helping to prevent complications and improve patient outcomes. Its targeted mechanism of action makes it a crucial therapeutic option for individuals with HAE.